parallel session number 1

Transcription

Save The Date
SCIENTIFIC PROGRAM SORTED BY SESSION TYPE
25 PARALLEL SESSIONS INCLUDING 4 PROFFERED PAPERS SESSIONS
PARALLEL SESSION NUMBER 1
CHAIRMEN: Hans Petter Eikesdal (Norway) and Fausto Roila (Italy)
ROOM CAPACITY: Large
TIME: Friday 09:00-10:30
NAME OF SESSION
Endocrine issues in cancer
Abstract 25-4-O
DURATION OF SESSION: 90 min
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Fausto Roila
Italy
Obesity, diabetes and cancer outcome
25 + 5 min
Pamela Goodwin
Canada
Hypothyroidism after radiotherapy
15 + 5 min
Marianne F Rønjom
Denmark
Endocrine disorders following treatment with tyrosine kinase inhibitors
20 + 5 min
Fausto Roila
Italy
7 + 3 min
Helga Schultz
Denmark
Hans Petter Eikesdal
Norway
INCIDENCE OF DIABETES INDUCED BY HIGH-DOSE GLUCOCORTICOID
TREATMENT IN CANCER PATIENTS
Conclusion
3 min
CHAIRMEN: Dorothy Keefe (Australia) and Birgitte Grube (Denmark)
ROOM CAPACITY: Medium
NAME OF SESSION
Use of E-Health in Supportive Care
PRESENTATION TITLE
Introduction
E-Health is empowered health
Nurses experience
How can e-health increase adherence to cancer therapy and supportive
care?
Physicians experience
E-health
Patients experience
Abstract 04-1-O
WEB-SUPPORTED INFORMATION NEEDS OF CAREGIVERS IN
HEMATOLOGIC CANCER
Conclusion
Minutes
3 min
SPEAKER
Dorothy Keefe
Australia
20 + 5 min
Bodil Westman
Sweden
20 + 5 min
Dorothy Keefe
Australia
20 + 5 min
Jane Pelouchova
Czech Republic
G Yigit
Turkey
Birgitte Grube
Denmark
7 + 3 min
2 min
CHAIRMEN: Patrick Combrez (Belgium) and Lars Kjeldsen (Denmark)
NAME OF SESSION
Best Supportive Care in Patients
with Haematological Malignancies
Abstract 08-2-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Patrick Crombez
Belgium
Supportive Care in Haematology
15 min
Lars Kjeldsen
Denmark
General Management of Neutropenic Patients
15 min
Patrick Crombez
Belgium
Nursing Evidence and Controverses in Infection Prevention
15 min
Arno Mank
The Netherlands
Outpatient Bone Marrow Transplantation
15 min
William Hogan
USA
Rossana Berardi
Italy
RISK OF HYPONATRAEMIA IN CANCER PATIENTS TREATED WITH
TARGETED THERAPIES: A META-ANALYSIS OF CLINICAL TRIALS.
Panel discussion
Conclusion
7 + 3 min
15 min
3 min
All
Lars Kjeldsen
Denmark
CHAIRMEN: Christoffer Steer (Australia) and Trine Lembrecht Jørgensen (Denmark)
NAME OF SESSION
Supportive Care in the Elderly
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Trine Lembrecht Jørgensen Denmark
Is Cancer Symptom Control Any Different in
Older Adult Cancer Patients?
20 + 2 min
Aminah Jatoi
USA
Pain control in the elderly
20 + 2 min
Eduardo Bruera
USA
Nursing Facilities and Cancer Supportive Care:
Providing Best Practices Clinical Services To Older Adult Cancer Patients
20 + 2 min
Bente Appel Esbensen
Denmark
Abstract 07-1-O
INPUT OF A PHARMACIST-LED MEDICATION EVALUATION IN THE
MANAGEMENT OF OLDER PATIENTS WITH CANCER
7 + 3 min
Myriam Aitichou
France
Abstract 07-2-O
CHARLSON COMORBIDITY INDEX AS A PREDICTOR OF OVERALL
SURVIVAL FOR PATIENTS WITH EARLY STAGE NSCLC?
7 + 3 min
Stefan S Jeppesen
Denmark
Christoffer Steer
Australia
Chairman’s conclusion
2 min
PROFFERED PAPERS - PARALLEL SESSION NUMBER 5
CHAIRMEN: Gilles Freyer (France) and Svend Ottesen (Denmark)
NAME OF SESSION
PRESENTATION TITLE
Psychooncology and Quality of Life
Introduction
18-1-O
CANCER CAREGIVER QUALITY OF LIFE: NEED FOR TARGETED
INTERVENTION
18-2-O
18-3-O
18-4-O
18-5-O
22-1-O
22-2-O
22-3-O
EXPECTATION EFFECTS IN ENDOCRINE TREATMENT OF BREAST CANCER:
A TWO-YEAR PROSPECTIVE CLINICAL COHORT STUDY
ESTROGEN RECEPTOR ALPHA (ESR1) GENETIC POLYMORPHISMS AND
THE RISK OF CHEMOTHERAPY-ASSOCIATED COGNITIVE IMPAIRMENT IN
EARLY-STAGE BREAST CANCER (ESBC) PATIENTS
RELATIONSHIP BETWEEN SUBJECTIVE AND ACTIGRAPHY-MEASURED
SLEEP IN 237 PATIENTS WITH METASTATIC COLORECTAL CANCER
(MCC)
THE CONTRIBUTION OF INFORMAL CAREGIVERS IN CANCER CARE, AND
PATIENT FACTORS ASSOCIATED WITH CAREGIVER OUTCOMES
QUALITY OF LIFE IN ELDERLY/FRAIL PATIENTS WITH GLIOBLASTOMA
MULTIFORME: RESULTS OF THE IAEA RANDOMIZED PHASE III STUDY
COMPARING SHORT AND STANDARD COURSE OF RADIOTHERAPY
VALIDATION OF THE EORTC QLQ-INFO 25 QUESTIONNAIRE IN LEBANESE
CANCER PATIENTS:
REVEALING A STATE OF BLISSFUL IGNORANCE?
CONFLICT, PARENT DISTRESS, FAMILY STRAIN AND HEALTH-RELATED
SYMPTOMS IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL)
Conclusion
Minutes
1 min
SPEAKER
Svend Ottesen
Denmark
8 + 3 min
Maria Lapid
USA
8 + 3 min
Yvonne Nestoriuc
Germany
Young Investigator Winner
8 + 3 min
Terence Ng
Singapore
Outstanding Young Investigator
8 + 3 min
Oxana Palesh
USA
8 + 3 min
Anna Ugalde
Australia
8 + 3 min
Elena Fidarova
Austria
8 + 3 min
Samer Tabchi
Lebanon
8 + 3 min
I-Chan Huang
USA
Gilles Freyer
France
1 min
CHAIRMEN: Marianne Ewertz (Denmark) and Michael Ewer (USA)
NAME OF SESSION
Cancer Therapy-Induced CardioPulmonary Toxicity
PRESENTATION TITLE
Introduction
Minutes
1 min
SPEAKER
Marianne Ewertz
Denmark
Michael Ewer
USA
Richard Gralla
USA
USA
Cardiotoxicity induced by chemotherapy and targeted therapy
35 + 4 min
Pulmonary toxicity induced by chemotherapy and targeted agents
25 + 4 min
Abstract 26-5-O
PRIMARY VERSUS SECONDARY CARDIOTOXICITY OF ANTI-CANCER
TREATMENT: A DISTINCTION WITH BROAD IMPLICATIONS
7 + 3 min
Michael Ewer
Abstract 24-6-O
RISK OF CARDIOVASCULAR DISEASE AMONG CANCER SURVIVORS
AND AGE- AND GENDER-MATCHED CONTROLS
7 + 3 min
Dounya Schoormans The Netherlands
Conclusion
1 min
Marianne Ewert
Denmark
CHAIRMEN: Siri Beier Jensen (Denmark) and Deborah P. Saunders (Canada)
NAME OF SESSION
Oral Care in Head and Neck Cancer
Abstract 15-1-O
Abstract 15-2-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Siri Beier Jensen
Denmark
Translating MASCC/ISOO research into patient-centered care:
Multidisciplinary phased oral care for patients undergoing head and neck
radiation
25 + 3 min
Deborah P. Saunders
Canada
Focus on taste disturbances
15 + 2 min
Anna Boltong
Australia
Focus on nutrition
15 + 2 min
Harriet Jager-Wittenaar The Netherlands
10 + 2 min
Ruta Zukauskaite
Denmark
10 + 2 min
Kristine Eidal Tanem
Norway
2 min
Deborah P. Saunders
Canada
STIMULATED RESIDUAL SALIVARY GLAND FUNCTION IS CORRELATED TO
MEAN RADIATION DOSE DELIVERED TO THE MAJOR SALIVARY GLANDS
DURING RADIOTHERAPY FOR HEAD AND NECK CANCER
ORAL AND DENTAL STATUS IN LONG- TERM SURVIVORS OF
ALLOGENEIC HSCT PERFORMED IN CHILDHOOD, ADOLESCENTS
OR YOUNG ADULTHOOD -PRELIMINARY RESULTS
Concluding remarks
Joint session FSK, EONS and MASCC
CHAIRMEN: Andreas Charalambous (Cyprus) and Alex Molassiotis (Hong Kong)
NAME OF SESSION
Complementary and Alternative
Medicine in Cancer Care
Abstract 04-2-O
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Alex Molassiotis
Hong Kong
CAM in Cancer Care: New data call for mind shifting?
20 min
Andreas Charalambous Cyprus
What is the evidence of CAM in cancer patients
20 min
Helle Johannessen
Denmark
Clinical Use of CAM in Cancer Patients
20 min
Alex Molassiotis
Hong Kong
COMPLEMENTARY MEDICINE EDUCATION FOR ONCOLOGY
PROFESSIONALS IN ALBERTA: EVALUATION OF AN ONLINE PROGRAM
7 + 3 min
Discussion
15 min
Conclusion
2 min
Gregory Levin
Canada
Andreas Charalambous Cyprus
CHAIRMEN: Jean Jacques Body (Belgium) and Carina Ørts Christensen (Denmark)
NAME OF SESSION
Bone Health
PRESENTATION TITLE
Introduction
Minutes
1 min
SPEAKER
Carina Ørts Christensen Denmark
Prevention of osteoporosis in cancer patients
15 min
Jean Jacques Body
Belgium
Bone metastases: what is new and what is targeted?
15 min
Matti S. Aapro
Switzerland
Recognition and management of osteonecrosis of the jaw
15 min
Cesar Migliorati
USA
Abstract 01-1-O
TREATMENT AND PREVENTION OF OSTEONECROSIS OF THE JAW
ASSOCIATED WITH MEDICATION:2009-2014
7 + 3 min
E. Papadopoulou
Greece
Abstract 01-2-O
PALLIATIVE SURGICAL INTENT IN THE TREATMENT OF BONE SARCOMAS:
A MIDTERM REVIEW FROM A RESOURCE CHALLENGED ENVIRONMENT
7 + 3 min
SA Khan
India
Abstract 01-3-O
RISK OF OSTEOPOROSIS SUBSEQUENT TO CHEMOTHERAPY FOR EARLYSTAGE BREAST CANCER
7 + 3 min
Carina Ørts Christensen Denmark
Optimising Bone Health: Discussion
Conclusion
12 min
2 min
All
Jean Jacques Body
Belgium
PROFFERED PAPERS - PARALLEL SESSION 10
CHAIRMEN: Andrea Cheville (USA) and Julie Silver (USA)
Time: Friday 14.30-16:00
NAME OF SESSION
Rehabilitation and survivorship
24-1-O
24-5-O
24-2-O
24-3-O
23-7-O
23-3-O
23-4-O
23-6-O
PRESENTATION TITLE
Minutes
Introduction
COMPARING THE COSTS OF THREE PROSTATE CANCER FOLLOW-UP
STRATEGIES:
A COST-MINIMISATION ANALYSIS
IMPLEMENTATION OF THE PROSTATE CANCER SUPPORTIVE CARE (PCSC)
PROGRAM, A COMPREHENSIVE APPROACH FOR MEN WITH PROSTATE
CANCER (PC) AND THEIR PARTNERS
QUALITY OF LIFE, HEALTH AND PERSONAL WELLBEING UP TO TWO
YEARS FOLLOWING CURATIVE INTENT COLORECTAL CANCER SURGERY:
RESULTS FROM THE UK COLORECTAL
WELLBEING (CREW) STUDY
PREOPERATIVE ANAEMIA AND BLOOD-TRANSFUSION AS PROGNOSTIC
FACTORS FOR MORTALITY IN COLORECTAL CANCER - A SWEDISH COHORT
STUDY
IMPROVING ADHERENCE TO CANCER TREATMENT BY ADDRESSING QUALITY OF
LIFE IN PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS
IMPACT AND FEASIBILITY OF AN EXERCISE PROGRAM DURING CHEMORADIOTHERAPY IN HEAD AND NECK CANCER SURVIVORS:A
RANDOMIZED CONTROLLED TRIAL
INSULIN-LIKE GROWTH FACTORS ARE MODULATED BY EXERCISE IN
BREAST CANCER SURVIVORS: A META-ANALYSIS WITH METAREGRESSION
SEXUALITY AND SEXUAL FUNCTION ONE YEAR AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Conclusion
1 min
SPEAKER
Andrea Cheville
USA
8 + 3 min
Alison Pearce
Jamaica
8 + 3 min
S L Goldenberg
Canada
Claire Foster
United
Kingdom
8 + 3 min
Malin Mörner
Sweden
8 + 3 min
J Basford
Canada
8 + 3 min
Stephen Samuel
India
8 + 3 min
Jose F M Echávez
Colombia
8 + 3 min
Kristina Nørskov
Denmark
Julie Silver
USA
8 + 3 min
1 min
CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South Africa)
NAME OF SESSION
Bone marrow toxicity
Abstract 26-2-O
Abstract 13-1-O
PRESENTATION TITLE
Introduction
Minutes
2 min
Mario Dicato
Luxembourg
Matti Aapro
Switzerland
Jean Klastersky
Belgium
William Hogan
USA
Mario Dicato
Luxembourg
7 + 3 min
G Birgegård
Sweden
7 + 3 min
D Kamioner
France
Bernardo Rapoport
South Africa
Anemia in cancer: an update of the use of iron, EPO and activin receptor
antagonists
17 + 3 min
Febrile neutropenia: an update of outpatient
management of low risk patients
12 + 3 min
Febrile neutropenia: an update of management of
high risk - stem cell transplantation patients
12 + 3 min
Thrombocytopenia and thrombopoietin
12 + 3 min
INTRAVENOUS IRON ISOMALTOSIDE 1000 (MONOFER®) AS MONO
THERAPY IN COMPARISON WITH ORAL IRON SULPHATE IN PATIENTS
WITH NON-MYELOID MALIGNANCIES ASSOCIATED WITH
CHEMOTHERAPY INDUCED ANAEMIA (CIA)
BIOSIMILAR FILGRASTIM AND CHEMOTHERAPY-INDUCED
NEUTROPENIA: OVERALL RESULTS OF THE NEXT STUDY
Conclusion
SPEAKER
3 min
CHAIRMEN: Mario Lacouture (USA) and Inge Marie Svane (Denmark)
ROOM CAPACITY: medium
NAME OF SESSION
Novel Therapies and Best
Supportive Care in Cutaneous
Malignancies
PRESENTATION TITLE
Introduction
Efficacy of agents targeting the BRAF/MEK pathway
Discussion
Efficacy of immune checkpoint inhibitors
Discussion
Systemic toxicities from BRAF/MEK pathway and Immune check point
inhibitors
Discussion
Dermatologic toxicities from BRAF/MEK pathway and Immune check
point inhibitors
Minutes
5 min
15 min
SPEAKER
Mario Lacouture
USA
Peter Arne Gerber
Germany
Inge Marie Svane
Denmark
Vincent Sibaud
France
Mario Lacouture
USA
Inge Marie Svane
Denmark
5 min
15 min
5 min
15 min
5 min
15 min
Discussion
5 min
Conclusion
5 min
CHAIRMEN: Petra Feyer (Germany) and Marianne Ewertz (Denmark)
NAME OF SESSION
Radiotherapy-induced Late
Toxicities in Cancer Survivors
Abstract 25-3-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Marianne Ewertz
Denmark
Late Complications Induced by Radiotherapy
in Head and Neck Cancer Patients
20 + 5 min
Petra Feyer
Germany
Carditoxicity induced by radiotherapy
20 + 5 min
Sarah C Darby
United Kingdom
Gastrointestinal late complications of radiotherapy
20 + 5 min
Ann Muls
United Kingdom
Mukesh Singhal
India
Petra Feyer
Germany
COMPARISON OF BENEFITS, SAFETY OF 8% VERSUS 4%
FORMALIN FOR TREATMENT OF CHRONIC HEMORRHAGIC
RADIATION PROCTITIS IN PATIENTS OF CERVICAL CARCINOMA:
A RANDOMIZED CONTROLLED TRIAL
Conclusion
7 + 3 min
3 min
PROFFERED PAPERS - PARALLEL SESSION 14
CHAIRMEN: Paul Hesketh (USA) and Rajesh Lalla (USA)
NAME OF SESSION
Gastro-intestinal toxicity
11-2-O
11-3-O
11-4-O
11-5-O
11-6-O
PRESENTATION TITLE
Introduction
ANTIEMESIS PROPHYLAXIS AMONG BREAST CANCER (BC) PATIENTS
RECEIVING ANTHRACYLINE-BASED CHEMOTHERAPY: A POPULATIONBASED STUDY.
EFFICACY AND SAFETY OF ROLAPITANT FOR PREVENTION OF
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER
MULTIPLE CYCLES OF HIGHLY- OR MODERATELY EMETOGENIC
CHEMOTHERAPY (HEC; MEC)
ROLE OF OLANZAPINE IN CHEMOTHERAPY INDUCED NAUSEA AND
VOMITING ON PLATINUM BASED CHEMOTHERAPY PATIENTS; A
RANDOMIZED CONTROLLED STUDY
THE ORAL ADMINISTRATION OF THE BRAIN PENETRATING GHRELIN
AGONIST, HM01, ANTAGONIZES CISPLATIN-INDUCED EMESIS IN SUNCUS
MURINUS (HOUSE MUSK SHREW)
SINGLE- VERSUS MULTIPLE-DAY CORTICOSTEROID DOSING FOR DELAYED
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Minutes
1 min
SPEAKER
Paul Hesketh
USA
8 + 3 min
Mariana Chavez
USA
Mac Gregor
8 + 3 min
Bernardo Rapoport
South Africa
8 + 3 min
Sandip Mukhopadhyay
India
8 + 3 min
John Rudd
Hong Kong
8 + 3 min
Pamela Ng
Canada
10-3-O
TIGHT JUNCTION DISRUPTION IS SEEN IN THE ORAL CAVITY OF PATIENTS
RECEIVING STANDARD DOSE CHEMOTHERAPY.
8 + 3 min
Hannah Wardill
Australia
10-4-O
DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED ASSESSMENT
TOOL FOR SYSTEMIC THERAPY-INDUCED DIARRHEA
8 + 3 min
Michelle Lui
Canada
10-5-O
ASSOCIATION BETWEEN ORAL MICROBIOME AND MUCOSITIS IN
HEMATOPOIETIC STEM CELL TRANSPLANT SUBJECTS
8 + 3 min
Farah Mougeot
USA
Rajesh Lalla
USA
Conclusion
1 min
CHAIRMEN: Matti Aapro (Switzerland) and Didier Kamioner (France)
TIME: Saturday 10:30-12:00
NAME OF SESSION
MASCC AFSOS Symposium
PRESENTATION TITLE
Introduction
Pharmacist in Cancer Care Unit;
A Role for Quality of Care?
Discussion
Back Home: Evidence for Supportive
Network; how, when and for who ?
Discussion
Mucositus Guidelines : An Update
Discussion
Breathlessness at the Palliative Time :
From Guidelines to Practice
Discussion
European Supportive Care Associations in MASCC:
from AFSOS to NICSO (Roundtable discussion)
Conclusion
Minutes
2 min
SPEAKER
Matti Aapro
Switzerland
Jean Baptiste Rey
France
Manon Lemonde
Canada
RJ Bensadoun
France
Claudia Mazzocato
Switzerland
25 min
Petra Feyer
Carla Ripamonti
Ivan Krakowski
Germany
Italy
France
3 min
Didier Kamioner
France
10 min
5 min
10 min
5 min
10 min
5 min
10 min
5 min
CHAIRMEN: Karin Olson (Canada) and Eric van Muilekom
NAME OF SESSION
Fatigue
Abstract 06-1-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Eric van Muilekom
The Netherlands
How do we define fatigue and what is new?
15 + 0 min
Karin Olson
Canada
Cancer-related sleep disturbances
15 + 5 min
Poul Jennum
Denmark
Compassion fatigue: How to deal with it?
15 + 5 min
Eric van Muilekom
The Netherlands
Fatigue in advanced cancer
15 + 5 min
Andreas Charalambous
Cyprus
Daniela Stan
USA
Karin Olson
Canada
RANDOMIZED TRIAL OF YOGA VERSUS STRENGTHENING EXERCISES IN
BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE
Conclusion
7 + 3 min
3 min
CHAIRMEN: Charles Loprinzi (USA) and Lise Eckhoff (Denmark)
NAME OF SESSION
Neurological Complications
PRESENTATION TITLE
Introduction
Minutes
1 min
SPEAKER
Charles Loprinzi
USA
Genomic risks for developing CIPN
20 + 3 min
Lise Eckhoff
Denmark
Treatment of CIPN
20 + 3 min
Charles Loprinzi
USA
Evidence-based caring for patients with CIPN
20 + 2 min
Anita Margulies
Switzerland
Abstract 12-1-O
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN MULTIPLE
MYELOMA PATIENTS: INFLUENCE ON QUALITY OF LIFE AND VALIDATION
OF A QUESTIONNAIRE FOR DAILY CLINICAL PRACTICE
7 + 3 min
Antoinetta Beijers
The Netherlands
Abstract 12-2-O
CAN PREGABALIN PREVENT PACLITAXEL-ASSOCIATED NEUROPATHY?—A
PILOT TRIAL
7 + 3 min
Shivani Shinde
USA
Lise Eckhoff
Denmark
Conclusion
1 min
PARALLEL SESSION NUMBER 18 joint session IASLC/MASCC
CHAIRMEN: Richard Gralla (USA) and tbd
TIME: Saturday 10.30-12:00
NAME OF SESSION
Supportive Care in Lung Cancer
Abstract 24-4-O
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Richard Gralla
USA
Management of NSCLC – state of the art
20 min
tbd
Dyspnea – magnitude of the problem and management
15 min
Sam Ahmedzai
United Kingdom
New options in the management of hyponatremia
10 min
Mellar Davis
USA
Quality of life in lung cancer
15 min
Richard Gralla
USA
7 + 3 min
Olfred Hansen
Denmark
Round table discussion
All
OVERALL SURVIVAL AFTER PALLIATIVE THORACIC RADIOTHERAPY FOR
LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER NOT SUITABLE
FOR CURATIVE INTENDED TREATMENT
How to optimize supportive care in lung cancer?
Conclusion
15 min
2 min
tbd
CHAIRMEN: Sebastiano Mercadante (Italy) and Sam Ahmedzai (United Kingdom)
NAME OF SESSION
Cancer Pain – Opioids and Beyond
Abstract 03-1-O
Abstract 03-2-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Sebastiano Mercadante Italy
Neuronal mechanisms and targeted therapy
of bone cancer pain
20 + 5 min
Understanding visceral pain - origins and treatments
15 + 5 min
Sebastiano Mercadante Italy
15 + 5 min
Eduardo Bruera
USA
7 + 3 min
Neal Slatkin
USA
7 + 3 min
Christine Miakowski
USA
Sam Ahmedzai
United
Kingdom
Cancer pain at the end of life – rational and realistic management
choices
EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMAB AS ADJUNCTIVE
THERAPY FOR CANCER-RELATED PAIN: A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, MULTICENTER STUDY
COMPARISON OF UPPER AND LOWER EXTREMITY CHARACTERIZATIONS
OF CHEMOTHERAPY-INDUCED NEUROPATHY (CIN) USING PATIENT
REPORTED OUTCOME MEASURES
Conclusion
3 min
Sam Ahmedzai
United
Kingdom
CHAIRMEN: Mario Lacouture (USA) and Jennifer Choi (USA)
ROOM CAPACITY: medium
NAME OF SESSION
Skin toxicity
PRESENTATION TITLE
Introduction
Assessment of skin toxicity
Case 1 (chemotherapy)
Minutes
5 min
20 min
5 min
SPEAKER
Jennifer Choi
USA
Christine Boers-Doets
NED
Mario Lacouture
USA
Discussion
10 min
Moderator:
Jennifer Choi
USA
State of the art: chemotherapy-induced skin toxicity
15 min
Mario Lacouture
USA
Jennifer Choi
USA
Case 2 (targeted therapy)
5 min
Discussion
10 min
Moderator:
Mario Lacouture
USA
State of the art: targeted therapy-induced skin toxicity
15 min
Jennifer Choi
USA
Mario Lacouture
USA
Conclusion
5 min
CHAIRMEN: Charles Loprinzi (USA) and Tom Møller (Denmark)
NAME OF SESSION
Supportive Care in Breast Cancer –
the Significance of Life Style
PRESENTATION TITLE
Introduction
Use of Exercise in Patients with Breast Cancer
Q&A
Healthy Diet and Lifestyle for Breast Cancer Patients
Q&A
Smoking as an Independent Risk Factor for Radiotherapy- Induced
Skin Reactions in Breast Cancer
Q&A
Abstract 26-3-O
Abstract 23-5-O
Abstract 09-1-O
RACIAL DIFFERENCES IN EARLY SYMPTOM MANAGEMENT, HOSPICE USE,
AND INTENSITY OF END-OF-LIFE CARE AMONG ELDERLY WOMEN WITH
BREAST CANCER
THE EFFECT OF EXERCISE TRAINING ON MEDIATORS OF TUMOUR
PROGRESSION IN BREAST CANCER SURVIVORS: A META-ANALYSIS
STANDARDIZING LYMPHEDEMA ASSESSMENT PRACTICES: A QUALITY
IMPROVEMENT INITIATIVE IN ALBERTA CANADA
Conclusion
Minutes
1 min
15 min
SPEAKER
Charles Loprinzi Loprinzi USA
Tom Møller
Denmark
Christina Lacerda
Portugal
Lena Sharp
Sweden
7 + 3 min
Devon Check
USA
7 + 3 min
Jose F M Echávez
Colombia
7 + 3 min
Margaret McNeely
Canada
Tom Møller
Denmark
5 min
15 min
4 min
15 min
4 min
1 min
CHAIRMEN: Richard Gralla (USA) and Jørn Herrstedt (Denmark)
NAME OF SESSION
Chemotherapy-induced nausea and
vomiting
Abstract 11-1-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Jørn Herrstedt
Denmark
Emetic risk classification of antineoplastic agents
15 + 5 min
Paul Hesketh
USA
Use of antiemetics targeting a single receptor
15 + 5 min
Karin Jordan
Germany
Use of antiemetics targeting multiple receptors
15 + 5 min
David Warr
Canada
Use of antiemetics in chemoradiation
12 + 3 min
Christina Ruhlmann
Denmark
Bahrat Amlani
United
Kingdom
Richard Gralla
USA
IMPACT AND MANAGEMENT OF CHEMOTHERAPY/ RADIOTHERAPYINDUCED NAUSEA AND VOMITING AND THE PERCEPTUAL GAP BETWEEN
ONCOLOGISTS/ONCOLOGY NURSES AND PATIENTS: A CROSS-SECTIONAL
MULTINATIONAL SURVEY
Conclusion
7 + 3 min
3 min
CHAIRMEN: Sharon Elad (USA) Ourania Nicolatou-Galitis (Greece)
NAME OF SESSION
Mucositis
Abstract 10-1-O
Abstract 10-2-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Ourania NicolatouGalitis
Greece
Update on low level laser therapy for oral mucositis
18 + 4 min
Sharon Elad
USA
Updates on clinical studies of palifermin for oral and
gastrointestinal mucositis
18 + 4 min
Nicole M. A. Blijlevens
The Netherlands
Stomatitis secondary to targeted anti-cancer agents
18 + 4 min
Ourania NicolatouGalitis
Greece
7 + 3 min
Rene-Jean Bensadoun
France
7 + 3 min
Alessandra Majorana
Italy
2 min
Sharon Elad
USA
CLONIDINE MUCOADHESIVE BUCCAL TABLET (CLONIDINE LAURIAD)
PREVENTS SEVERE RADIOMUCOSITIS IN HEAD AND NECK CANCER
PATIENTS: A PHASE II RANDOMIZED TRIAL
EFFECTIVENESS OF LOW-LEVEL LASER THERAPY IN THE PREVENTION
AND TREATMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN
CHILDREN
Conclusion
CHAIRMEN: Andrea Cheville (USA) and Ann-Dorthe Olsen Zwisler (Denmark)
NAME OF SESSION
Rehabilitation
Abstract 23-1-O
Abstract 23-2-O
PRESENTATION TITLE
Introduction
Minutes
2 min
SPEAKER
Andrea Cheville
USA
Lessons to be learned from rehabilitation of non-cancer patients
15 + 5 min
Ann-Dorthe Olsen
Zwisler
Denmark
Rehabilitation of older adults with cancer
15 + 5 min
Christoffer Steer
Australia
Optimization of Cancer Rehabilitation
20 + 5 min
Andrea Cheville
USA
8 + 3 min
Mary Jarden
Denmark
8 + 3 min
Thomas Hack
Canada
Ann-Dorthe Olsen
Zwisler
Denmark
PATIENT ACTIVATION THROUGH COUNSELING AND EXERCISE – ACUTE
LEUKEMIA (PACE-AL) TRIAL – A RANDOMIZED CONTROLLED TRIAL
THE MEDIATING ROLE OF PERCEIVED DISABILITY IN THE LONG-TERM
IMPACT OF ARM MORBIDITY ON BREAST CANCER SURVIVORS'
EMOTIONAL WELL-BEING
Conclusion
1 min
CHAIRMEN: Declan Walsh (Ireland) and Eduardo Bruera (USA)
NAME OF SESSION
Nutrition and cancer cachexia
14-1-O
14-2-O
14-3-O
14-4-O
02-1-O
02-2-O
02-3-O
02-4-O
PRESENTATION TITLE
Introduction
SWALLOW ASSESSMENT IN HEAD AND NECK CANCER PATIENTS TREATED
WITH MULTI-MODALITY THERAPY: COMPARISON OVER TIME OF SELFREPORT, PHYSICAL EXAM FINDINGS AND OBJECTIVE MEASURES (R01
CA149113-01A1)
DIETARY AND EXERCISE INTERVENTIONS TO IMPROVE QUALITY OF LIFE,
METABOLIC RISK FACTORS AND ANDROGEN DEFICIENCY SYMPTOMS IN
MEN WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION
THERAPY
CANCER MALNUTRITION AND CLINICAL OUTCOMES: RESULTS FROM
TWO POINT PREVALENCE STUDIES IN AUSTRALIA
EXPLORING POTENTIAL BENEFIT OF EARLIER NUTRITIONAL
INTERVENTIONS IN ADULTS WITH UPPER GASTROINTESTINAL CANCER: A
RANDOMISED TRIAL
RESULTS FROM ROMANA 1 AND 2: TWO PHASE III TRIALS OF ANAMORELIN IN
ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH CACHEXIA
RESULTS FROM ROMANA 3: A SAFETY EXTENSION STUDY OF
ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
WITH CACHEXIA
IMPACT OF CANCER CACHEXIA ON THE PHARMACOLOGY AND TOXICITY
OF CHEMOTHERAPY (5-FU, PACLITAXEL) AND THE ORAL TYROSINE
KINASE INHIBITOR ERLOTINIB: A RETROSPECTIVE PILOT STUDY (CAT)
VALIDATING ASSESSMENT OF SKELETAL MUSCLE MASS (SMM) AT L1 ON
CHEST CT SCAN IN EVALUATING CANCER CACHEXIA (CC) AND
SARCOPENIA IN PATIENTS WITH LUNG CANCER
Conclusion
Minutes
1 min
SPEAKER
Declan Walsh
Ireland
8 + 3 min
M Maddalo
Italy
8 + 3 min
L Teleni
Australia
8 + 3 min
K Marshall
Australia
8 + 3 min
MA Silvers
Australia
8 + 3 min
A Abernethy
USA
8 + 3 min
D Currow
Australia
F Strasser
Switzerland
A Recio-Boiles
USA
Eduardo Bruera
USA
8 + 3 min
8 + 3 min
1 min
3 PLENARY SESSIONS
PLENARY SESSION NUMBER 1
CHAIRMEN: David Warr (Canada) and Jørn Herrstedt (Denmark)
TIME: Thursday 12:45-13:45
NAME OF SESSION
Supportive Care is a Continuum
PRESENTATION TITLE
Introduction to session and Einhorn
Late Toxicities Induced by Anti-Neoplastic Agents;
a Half Century Evaluation of Advantages and Challenges
Introduction Silver
The Role of Prehabilitation and Rehabilitation in High-Quality Cancer
Care
Closure
Minutes
2 min
28 min
1 min
28 min
1 min
SPEAKER
David Warr
Canada
Lawrence H Einhorn
USA
Jørn Herrstedt
Denmark
Julie Silver
USA
Jørn Herrstedt
Denmark
CHAIRMEN: David Warr (Canada) and Marianne Ewertz (Denmark)
NAME OF SESSION
PRESENTATION TITLE
Pharmaceutical Supportive Care
Introduction to session and Chan
Steven Grunberg Award Session
Pharmacogenomics in Supportive Care
Introduction Lassen
Unmasking Side Effects from “First-in-Man” Antineoplastic Medicine
Introduction Keefe
New Developments in Personalised
Supportive Care Medicine
Closure
Minutes
3 min
SPEAKER
David Warr
Canada
18 min
Alexandre Chan
Singapore
1 min
Marianne Ewertz
Denmark
18 min
Ulrik Lassen
Denmark
1 min
David Warr
Canada
Dorothy Keefe
Australia
Marianne Ewertz
Denmark
18 min
1 min
CHAIRMEN: Lawrence H Einhorn (USA) and Declan Walsh (IRL)
NAME OF SESSION
The Oncologic Tsunami
PRESENTATION TITLE
Introduction to session and Gosney
Older Cancer Patients Survive – are we prepared?
Introduction Olver
Reality of Supportive Care in the Developing World
Closure
Minutes
2 min
28 min
2 min
28 min
1 min
SPEAKER
Declan Walsh
Ireland
Margot A Gosney
United Kingdom
Lawrence H Einhorn
USA
Ian Olver
Australia
Declan Walsh
Ireland
3 PRO ET CON SESSIONS
PRO ET CON SESSION NUMBER 1
CHAIRMEN: Alex Chan (Singapore)
NAME OF SESSION
Antithrombotic agents for every
patient with incurable cancer?
PRESENTATION TITLE
Introduction and voting
Minutes
5 min
SPEAKER
Alex Chan
Singapore
PRO
20 min
Mario Dicato
Luxemburg
CON
20 min
Florian Strasser
Switzerland
Discussion and new voting
15 min
Alex Chan
Singapore
CHAIRMAN: Sam Ahmedzai (United Kingdom)
NAME OF SESSION
Euthanasia, assisted dying
PRESENTATION TITLE
Minutes
5 min
SPEAKER
Sam Ahmedzai
United
Kingdom
PRO
20 min
Dominique Lossignol
Belgium
CON
20 min
Gilles Freyer
France
15 min
Sam Ahmedzai
United
Kingdom
CHAIRMAN: Declan Walsh (Ireland)
NAME OF SESSION
Parenteral nutrition in advanced
cancer
PRESENTATION TITLE
Minutes
5 min
SPEAKER
Declan Walsh
Ireland
PRO
20 min
Florian Strassser
Switzerland
CON
20 min
Eduardo Bruera
USA
15 min
Declan Walsh
Ireland
7 CHALLENGE YOUR EXPERT SESSIONS
CHALLENGE YOUR EXPERT SESSION NUMBER 1
CHAIRMAN: Fausto Roila (Italy)
EXPERT: Mellar Davis (USA)
NAME OF SESSION
Management of nausea and
vomiting in advanced cancer
PRESENTATION TITLE
Introduction
Minutes
SPEAKER
3 min
Fausto Roila
Italy
State of the art lecture
25 min
Mellar Davis
USA
Discussion
15 min
All
Conclusion
2 min
Fausto Roila
Italy
CHAIRMAN: Eduardo Bruera (USA)
EXPERT: Declan Walsh (Ireland)
NAME OF SESSION
Use of cannabinoids in cancer
therapy and supportive care
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Eduardo Bruera
USA
Ireland
25 min
Declan Walsh
Discussion
15 min
All
Conclusion
2 min
Eduardo Bruera
USA
CHAIRMAN: Svend Saalbach Ottesen (Denmark)
EXPERT: Eduardo Bruera (USA)
NAME OF SESSION
Management of patients with
delirium
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Svend Saalbach Ottesen Denmark
25 min
Eduardo Bruera
Discussion
15 min
All
Conclusion
2 min
USA
Svend Saalbach Ottesen Denmark
CHAIRMAN: Aminah Jatoi (USA)
EXPERT: Florian Strasser (Switzerland)
NAME OF SESSION
Nutrition and Cancer Cachexia
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Aminah Jatoi
USA
Switzerland
25 min
Florian Strasser
Discussion
15 min
All
Conclusion
2 min
Aminah Jatoi
USA
CHAIRMAN: Mellar Davis (USA)
EXPERT: Mario Dicato (Luxembourg)
NAME OF SESSION
Cancer and Thrombosis
PRESENTATION TITLE
Introduction
Minutes
SPEAKER
3 min
Mellar Davis
USA
25 min
Mario Dicato
Luxembourg
Discussion
15 min
All
Conclusion
2 min
Mellar Davis
USA
CHAIRMAN: Bernardo Rapoport (South Africa)
EXPERT: Jean Klastersky (Belgium)
NAME OF SESSION
Fever of Unknown Origin
PRESENTATION TITLE
Introduction
Minutes
3 min
SPEAKER
Bernardo Rapoport
South Africa
Belgium
25 min
Jean Klastersky
Discussion
15 min
All
Conclusion
2 min
Bernardo Rapoport
South Africa
CHALLENGE YOUR EXPERTS SESSION NUMBER 7
CHAIRMAN: Fred Ashbury (Canada)
NAME OF SESSION
How to prepare and submit a paper
for Supportive Care in Cancer
EXPERTS: Fred Ashbury (Canada), Paul Hesketh (USA) and Ian Olver (Australia)
PRESENTATION TITLE
Introduction
Minutes
SPEAKER
5 min
Fred Ashbury
Canada
The editors view
10 min
Fred Ashbury
Canada
The authors view
20 min
Paul Hesketh
USA
The reviewers view
20 min
Ian Olver
Australia
Discussion
30 min
All
Conclusion
5 min
Fred Ashbury
Canada
6 PROFFERED PAPERS AND EXPERTS OPINIONS SESSIONS
PROFFERED PAPERS AND EXPERTS OPINIONS 1
CHAIRMEN AND EXPERTS: Dorothy Keefe (Australia) and Mario Lacouture (USA)
TIME: Thursday 16.15-17:15
NAME OF SESSION
PRESENTATION TITLE
Minutes
SPEAKER
Toxicity of targeted agents
Introduction to session and to toxicity of targeted agents
2 min
Dorothy Keefe
Australia
Abstract 25-1-O
META-ANALYSIS: HYPERTENSION RISK IN SELECTED TARGETED AGENTS
8 min
Carmelita Escalante
USA
Abstract 26-7-O
ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH
NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB
(N) AND DOCETAXEL (D)
8 min
Anders Mellemgaard
Denmark
Dorothy Keefe
Australia
1 min
Mario Lacouture
USA
8 min
Jeroen Mebis
Belgium
1 min
Sergejs Kuznecovs
Latvia
12 min
Mario Lacouture
USA
1 min
Mario Lacouture
USA
Expert opinion abstracts 25-1-O and 26-5-O
Skin toxicity
Abstract 20-1-O
Abstract 20-2-O
Introduction skin toxicity
LOW LEVEL LASER THERAPY FOR THE MANAGEMENT OF RADIATION
DERMATITIS: FINAL RESULTS OF THE DERMIS TRIAL, A PILOT STUDY
IN BREAST CANCER PATIENTS
PALMAR PLANTAR ERYTHRODYSESTHESIA PREVENTION WITH
ATORVASTATIN AND POLYPRENOL
Closure
12 min
CHAIRMEN AND EXPERTS: Fausto Roila (Italy) and Charles Loprinzi (USA)
NAME OF SESSION
Bone complications and
chemotherapy-induced nausea
and vomiting
Abstract 27-3-O LBA
Abstract 27-2-O LBA
PRESENTATION TITLE
Introduction
PREVALENCE OF LOW BONE MASS AND OSTEOPOROSIS IN
WOMEN DIAGNOSED WITH GYNECOLOGIC CANCER
A RANDOMIZED, PHASE 3, DOUBLE-BLIND STUDY OF INTRAVENOUS
FOSAPREPITANT AS A SINGLE DOSE FOR PREVENTING HEMOTHERAPYINDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY
EMETOGENIC CHEMOTHERAPY
Minutes
SPEAKER
1 min
Fausto Roila
Italy
8 min
Beatrice Edwards
USA
8 min
Bernardo Rapoport
South Africa
Fausto Roila
Italy
12 min
Neurological complications
Introduction
1 min
Charles Loprinzi
USA
Abstract 27-1-O LBA
PREVENTION OF NEUROPATHY USING CALMANGAFODIPIR (PLEDOX®):
RESULTS FROM A PHASE I STUDY AND A PLACEBO-CONTROLLED
RANDOMIZED STUDY (PLIANT) IN PATIENTS WITH METASTATIC
COLORECTAL CANCER (MCRC)
8 min
Bengt Glimelius
Sweden
Expert opinion abstract 27-1-O
6 min
Charles Loprinzi
USA
Closure
1 min
Charles Loprinzi
USA
CHAIRMEN AND EXPERTS: Florian Strasser (Switzerland) and Alexander Chan (Singapore)
ROOM CAPACITY: Small
NAME OF SESSION
PRESENTATION TITLE
Minutes
SPEAKER
Palliative Care
Introduction palliative care
1 min
Florian Strasser
Switzerland
Abstract 17-1-O
A DIAGNOSTIC MODEL FOR IMPENDING DEATH IN
PATIENTS WITH ADVANCED CANCER
8 min
David Hui
USA
Abstract 05-1-O
PROGNOSTIC EVALUATION IN PALLIATIVE CARE: FINAL RESULTS
FROM A PROSPECTIVE COHORT STUDY
8 min
Paola Ermacora
Italy
12 min
Florian Strasser
Switzerland
Abstract 17-2-O
CHEMICAL COMPATIBILITY/STABILITY OF COMMONLY USED DRUG
COMBINATIONS ADMINISTERED BY CONTINUOUS SUBCUTANEOUS
INFUSIONS FOR END OF LIFE CARE
8 min
Andrew Dickman
United
Kingdom
Expert opinion abstract 17-2-O
7 min
Alexander Chan
Singapore
Closure
1 min
Alexander Chan
Singapore
CHAIRMEN AND EXPERTS: Rajesh Lalla (USA) and Alexis Molassiotis (Hong Kong)
ROOM CAPACITY: Small
NAME OF SESSION
Evidence-based guidelines
Abstract 19-1-O
Abstract 25-2-O
PRESENTATION TITLE
Introduction to session and to development of guidelines
DEVELOPING AN EVIDENCE-BASED GUIDELINE FOR MANAGEMENT OF
DYSPNEA IN CANCER PATIENTS: DESCRIPTION OF MASCC RESPIRATORY
STUDY GROUP TASK
PROACTIVE APPROACH: DEVELOPING AND IMPLEMENTING GUIDELINES
FOR TREATING PATIENTS WITH ORALLY-ADMINISTERED ANTI-CANCER
DRUGS (OAACD) IN THE HOME-CARE SETTING: EXPERIENCE OF A
COMPREHENSIVE CANCER CENTER
Education
Abstract 04-3-O
Abstract 04-4-O
Introduction education
ONCOLOGY NURSING SOCIETY (ONS) PUTTING EVIDENCE INTO PRACTICE
(PEP): SYNTHESIS OF EVIDENCE BASED INTERVENTIONS FOR
ADHERENCE TO ORAL AGENTS FOR CANCER
STRENGTHS, WEAKNESSES AND AREAS FOR IMPROVEMENTS: A
COMPARATIVE SURVEY OF UNDERGRADUATE PALLIATIVE CARE (PC)
EDUCATION ACROSS ALL UK MEDICAL SCHOOLS (MS)
Closure
Minutes
SPEAKER
2 min
Rajesh Lalla
USA
8 min
Sam Ahmedzai
United
Kingdom
8 min
Tal Granot
Israel
12 min
Rajesh Lalla
USA
1 min
Alex Molassiotis
Hong Kong
8 min
Cynthia Rittenberg
USA
8 min
Steven Walker
United
Kingdom
12 min
Alex Molassiotis
Hong Kong
1 min
Alex Molassiotis
USA
CHAIRMEN AND EXPERTS: Ian Olver (Australia) and Mellar Davis (USA)
NAME OF SESSION
Palliative care
Abstract 17-3-O
Abstract 17-4-O
PRESENTATION TITLE
Introduction to session and to palliative care
EXPLORING THE COMPLEXITIES OF CAREGIVER QUALITY OF LIFE:
QUALITATIVE RESULTS FROM A TRIAL OF EARLY PALLIATIVE CARE
DIFFERENCES IN ATTITUDES AND BELIEFS TOWARD CANCER
TREATMENTS AT THE END-OF-LIFE BETWEEN HEMATOLOGIC AND SOLID
TUMOR ONCOLOGY SPECIALISTS
Abstract 17-5-O
Abstract 17-6-O
THE FREQUENCY, CHARACTERISTICS AND OUTCOMES AMONG CANCER
PATIENTS WITH DELIRIUM ADMITTED TO AN ACUTE PALLIATIVE CARE
UNIT (APCU)
SLEEP DISTURBANCE CONTRIBUTES TO CRF IN CANCER PATIENTS WITH
ACTIVE DISEASE
Closure
Minutes
SPEAKER
2 min
Ian Olver
Australia
8 min
Julie McDonald
Canada
8 min
David Hui
USA
12 min
Ian Olver
Australia
8 min
Maxine de la Cruz
USA
8 min
Diwakar Balachandran
USA
12 min
Mellar Davis
USA
2 min
Mellar Davis
USA
CHAIRMEN AND EXPERTS: Aminah Jatoi (USA) and Sam Ahmedzai (United Kingdom)
NAME OF SESSION
Pediatrics
Abstract 16-1-O
Abstract 16-2-O
PRESENTATION TITLE
Introduction to session and to pediatrics
DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR SUPPORTIVE
CARE IN CHILDHOOD CANCER IN THE NETHERLANDS – CURRENT
VARIATIONS IN SUPPORTIVE CARE PRACTICE
TOXICITY IS ASSOCIATED WITH AGE AND BODY MASS INDEX IN NOPHOAML 2004
Minutes
SPEAKER
2 min
Aminah Jatoi
USA
8 min
Erik Loeffen
The Netherlands
8 min
Ditte Juel A Løhmann
Denmark
Aminah Jatoi
USA
12 min
Patient Care
Introduction to care coordination
1 min
Sam Ahmedzai
United Kingdom
Abstract 26-1-O
CARE COORDINATION EXPERIENCE OF PATIENTS WITH COLORECTAL
CANCER: A POPULATION BASED STUDY
8 min
Ivana Durcinoska
Australia
Abstract 26-6-O
PATIENT SATISFACTION WITH CANCER-RELATED CARE: LANGUAGEBASED DIFFERENTIAL ITEM FUNCTIONING.
8 min
Jean-Pierre Pascal
USA
12 min
Sam Ahmedzai
United Kingdom
1 min
Sam Ahmedzai
United Kingdom
Expert opinion abstracts
Closure
1 POSTER DISCUSSION SESSION
POSTER DISCUSSION 1
CHAIRMEN AND EXPERTS: Jean Klastersky (Belgium) and Mario Dicato (Luxembourg)
NAME OF SESSION
Febrile neutropenia
Abstract 13-2-O
Abstract 13-3-O
Abstract 13-4-O
PRESENTATION TITLE
Introduction febrile neutropenia
Practical Application of a Febrile Neutropenia Pre-Printed Order
/Algorithm Incorporating the MASCC Index within a Large Regional
Emergency Department
ASSESSMENT OF A NOMOGRAM FOR PREDICTING SERIOUS
COMPLICATIONS IN PATIENTS FROM THE UNIVERSITY OF SALAMANCA
HOSPITAL FEBRILE NEUTROPENIA REGISTRY
NORTHERN IRELAND'S EXPERIENCE OF IMPROVING INITIAL
NEUTROPENIC SEPSIS MANAGEMENT THROUGH A MULTIDISCIPLINARY
INTEGRATED CARE PATHWAY
Discussion abstracts 13-2-O, 13-3-O and 13-4-O
Minutes
SPEAKER
1 min
Jean Klastersky
Belgium
3 min
Lee Ann Martin
Canada
3 min
Ignacio Matos
Spain
3 min
Caroline Forde
United
Kingdom
12 min
Jean Klastersky
Belgium
Anemia and thrombosis
Introduction anemia and thrombosis
1 min
Mario Dicato
Luxembourg
Abstract 08-1-O
TRAJECTORY OF HEMOGLOBIN LEVEL DURING TREATMENT OF SELECTED
MYELOSUPPRESSIVE CHEMOTHERAPY REGIMENS FOR BREAST CANCER
3 min
Chun Chao
USA
Abstract 26-4-O
LEANING UPON INTERNATIONAL DIRECTIVES FOR OPTIMIZATION:
ANEMIA
3 min
V Launay-Vacher
France
Abstract 21-1-O
VENOUS THROMBOLISM IN CANCER- A PROSPECTIVE STUDY
3 min
Aruna Alahari Dhir
India
12 min
Mario Dicato
Luxembourg
1 min
Mario Dicato
Luxembourg
Discussions posters 08-1-O, 26-4-O and 21-1-O
Closure
IN ADDITION 5 SATELLITE SYMPOSIA AND ONE SPONSORED MEET
THE EXPERT SESSION (NOT PART OF THE SCIENTIFIC PROGRAM)

parallel session number 1

Transcription

Similar documents